Apexigen, Inc.

Pdl Biopharma, Inc.

Jiangsu Simcere Pharmaceutical R&d Co., Ltd

Jiangsu Simcere Pharmaceutical Co., Ltd

Yongke Zhang

Weimin Zhu

Guo-Liang Yu

Yaohuang Ke

Sum Wai Pierre Lee

Vanitha Ramakrishnan

Debbie Law

Xiaodong Yang

Guoliang Yu

Fanxin Ma

Xin Fan

Pierre Li

The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.

Anti-CD40 antibodies

The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.

Anti-RANKL antibodies and methods of use

The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.

Anti-IL-6 receptor antibodies and methods of use

Anti-CD40 antibodies and methods of use

The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.

Anti-KDR antibodies and methods of use

Methods of inhibiting proliferation of CD40-expressing cancer cells with anti-CD40 antibodies

The present invention provides anti-IL-1&#x3b2; monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and other diseases.

Anti-IL-1&#x3b2; antibodies

The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.

Anti-VEGF monoclonal antibody and pharmaceutical composition comprising said antibody

Polynucleotides encoding anti-CD40 antibodies

Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.

Growing community of inventors

Palo Alto, CA, United States of America

Yongke Zhang